Upload
valentine-potter
View
214
Download
0
Embed Size (px)
Citation preview
1
"THE A, B, C'S OF TECHNOLOGY START-
UPS."
UNIVERSITY VIEW by
MELVIN J. DEGEETER, PH.D.
www.tclearningcenter.com
2
OVERVIEW
UNIVERSITY TECHNOLOGY
STARTUP
YES NO
3
OVERVIEW
GETTING TO YES:
FEDERAL, STATE, INSTITUTIONAL POLICIES/STATUTES
TECHNOLOGY ASSESSMENT
STARTUP QUALIFICATIONS
4
OVERVIEW
IF YES THEN:
CANDIDATE SELECTION
OPTION OR LICENSE?
EQUITY OR NO EQUITY?
5
FEDERAL STATUTES, LEGISLATION, ASSISTANCE
BAYH DOLE
GRANT TERMS
COLLABORATION RIGHTS
IMPORT/EXPORT REQUIREMENTS
SMALL BUSINESS PROGRAMSAGENCIES (SBIR, STTR, CRADA,
ETC.)SBANATIONAL LABORATORIES
6
STATE STATUTES OR PROGRAMS
EQUITY ALLOWED OR NOTLIMITATIONS ON SECURITIES
GRANT TERMSSTATE ORGANIZATIONSFOUNDATIONS/TRADE ASSOCIATIONS
ASSISTANCEBUSINESS PLANS, CAPITALIZATION
(“BRIDGE” FUNDS), INFORMATION BASE (GRANTS, CoC, INCUBATORS, ETC.)
7
INSTITUTION POLICY(IES) OR PROCEDURES
EQUITY (SEPARATE OR PART OF CONFLICT OR IP POLICY(IES), DIRECTIVE OR MANAGED)
TYPE (MEMBERSHIP SHARES VS. STOCK)
QUANTITY (HOW MUCH IS TOO MUCH?)
SELL OR BUY - PRE IPO, AT IPO OR AFTER IPO? (AVOID INFLUENCE; REAL OR PERCEIVED)
DISTRIBUTION (UPON RECEIPT, WHEN CASHED OR ??)
TAX AND/OR UBIT CONSEQUENCES
8
INSTITUTION POLICY(IES) OR PROCEDURES
EQUITY
WAIVE ROYALTY IN LIEU OF EQUITY?
(IS IT COMPANY OR UNIVERSITY CREATOR WORKS FOR? MAY WANT TO REQUIRE FACULTY TO WAIVE ROYALTY RIGHTS IF EQUITY PROVIDED TO THEM BY COMPANY.)
9
INSTITUTION POLICY(IES) OR PROCEDURES
BOARD OF DIRECTORS
IF NO PAY TO UNIV. OR INDIVIDUAL CONFLICT MAY NOT BE AN ISSUE
MEMBER HAS FIDUCIARY DUTY TO COMPANY
VOTING OR NON VOTING SEAT
10
INSTITUTION POLICY(IES) OR PROCEDURES
CONFLICTS UNFAIR COMPETITION
"SHOP" ASSET
"PREFERRED" RELATIONSHIP
FACILITY USE BY CO. (RESEARCH & TEACHING INTERFERENCE, CO. “RENT”, RIVAL FIRM COLLABORATION)
EXTENT OF DISCLOSURE ABOUT EQUITY DEAL? (DETAIL OR NAME, TOPIC & CO. NAME)
11
INSTITUTION POLICY(IES) OR PROCEDURES
CONFLICTSINTEREST
OUTSIDE FIRM TO MANAGE EQUITY POOL?
CONTINUE RESEARCH AT UNIV. OR ?
COMMITMENT TO SOCIETY VS. $$$ GAIN
EQUITY IN CO. MAY INFLUENCE DECISIONS ON CHOICE OF PRODUCTS OR TESTS (AVOID LATE STAGE R&D PARTICIPATION?)
12
INSTITUTION POLICY(IES) OR PROCEDURES
CONFLICTSCOMMITMENT
STUDENT EXPLOITATION
FACULTY TIME/CONSULTING TERMS
FACULTY OWNED COMPANY CONCERNS (I.E., EMPLOYEE AGREEMENT USUALLY REQUIRES ASSIGNMENT OF IP TO CO.)
13
INSTITUTION POLICY(IES) OR PROCEDURES
CONFLICT MANAGEMENT IS KEY
BOARD SEATS, VOTING RIGHTS, ANTI-DILUTION RIGHTS, OWNERSHIP RETENTION, WARRANTS OR OPTIONS, ETC.
PROTECT INTERNAL ACTIVITIES & DESIRES E.G. PROMOTION & TENURE, RESEARCH AGENDAS
PROTECT FROM EXTERNAL ISSUES; E.G. LAW SUITS, PUBLIC RELATIONS & FINANCIAL LOSS
14
INSTITUTION POLICY(IES) OR PROCEDURES
OTHER CONSIDERATIONS MANY LICENSES GO TO SMALL COMPANIES
INVENTIONS MAY NOT APPEAL TO LARGE CO.
SMALL BIZ CANNOT AFFORD DESIRED PRICE
LOCAL ECONOMIC DEVELOPMENT SUCCESS
ALLOWS ASSET TRANSFER THAT: 1. MAY NOT BE TRANSFERRED
OTHERWISE2. WILL RESULT IN VERY LOW “ROI” 3. OPENS DOOR FOR EQUITY ACCEPTANCE
15
INSTITUTION POLICY(IES) OR PROCEDURES
OTHER CONSIDERATIONS
EQUITY DIVERTS DEPENDENCE ON SUCCESS OF TECHNOLOGY TO SUCCESS OF COMPANY
FACULTY SATISFACTION – ATTRACT & RETAIN
FINANCIAL RETURN POTENTIAL
ENHANCED TT ("FULL SERVICE TT”)
16
INSTITUTION POLICY(IES) OR PROCEDURES
“BUFFER” ORGANIZATION
ADDRESSES INFRINGEMENT, LIABILITY, PATENT LITIGATION, CONTRACT DISPUTE & MONITORING, PUBLIC RELATIONS, IMAGE PERCEPTIONS, & MGNT PROCUREMENT
REDUCE CONTROL & INVOLVEMENT BY UNIV.
SECURITIES MANAGED BY EXTERNAL PRO
SECURITIES DISTRIBUTED TO CREATOR(S)
MANAGES EXPENSE RECOVERY
COST = ?
17
INSTITUTION POLICY(IES) OR PROCEDURES
CONCLUSION
NO SET OF POLICIES CAN ADEQUATELY ADDRESS EVERYTHING - SO MANAGE, COMMUNICATE & REPORT
OWNERSHIP ROLE REQUIRES CAREFUL REVIEW OF START UP’S BUSINESS PLAN
CULTURE & OBJECTIVES DIFFER BETWEEN UNIVERISTY & INVESTORS SO AVOID MISUNDERSTANDINGS
18
TECHNOLOGY/ASSET EVALUATION/VALUATION
NUMEROUS EVAL./VALUATION PROCEDURES AVAILABLE (RISK ADJUSTED NPV)
SOME KEY TERMS:INTELLECTUAL PROPERTYDEFINITIONSGRANTCOMPENSATIONREPORTS/REPORTINGTERM AND TERMINATIONRISK/BENEFIT ANALYSIS
19
START-UP CONSIDERATIONSBROKER, RESEARCH, DEVELOP, MARKET, R&D, D&M OR RD&M ROLE?
OPTION OR NOT?
MARKET SIZE - >$100M (>$400M IF PHARMA)
PROPRIETARY POSITION
CORE OR PERIPHERAL TO BUSINESS
20
START-UP CONSIDERATIONS
KNOWLEDGEABLE & COMPATIBLE MGNT
CAPITALIZATION STATUS & PLAN
COMPETITION – NOW & FUTURE
MARKETING STRENTHS (B2B, HOME MARKET)
21
COMPANY DUE DILIGENCE
SEE HANDOUT FOR CHECKLIST
DUE DILIGENCE (MORE THAN JUST ASSET)
QUALIFICATIONSTECHNICALPHYSICAL FACILITIES
SUBCONTRACT?
22
COMPANY DUE DILIGENCE
EVALUATE BUSINESS PLAN R&D PLAN (VISITING SCIENTIST, SABATICAL, MATERIAL EXCHANGE, ??)REGULATORY STRATEGY & PLANMARKET PLAN
ENTRY DATEMARKET STRATEGIES PROJECTED MARGINS ESTIMATED SALES
CAPITALIZATION PLAN
23
COMPANY DUE DILIGENCE
SECURTIES
TYPE, QUANTITY, WHEN (STOCK/SHARES)
DISTRIBUTION - CURRENT, PLANNEDCO. EMPLOYEES, INVESTORS,
PARTNERSSECURITIES REGISTRATION
EXAMINE CO. AGREEMENTS
DILUTION OR NOT (X INVESTMENT ROUND)
RESPONSIBLE PARTY(IES) - WHO
24
COMPANY DUE DILIGENCESECURTIES (CONTINUED)
AUDIT RIGHTS
EXIT PLANINITIAL PUBLIC OFFERINGBUYOUT
BUY-OUTPROVISIONS & CONSIDERATIONWHAT HAPPENS TO LICENSE?SUBLICENSE TERMS?
25
BOTTOM LINE
IF EQUITY DESIRED THEN IT IS NECESSARY TO:
“THINK & DO AS INVESTOR DOES”
26
THANK YOU